◆ 会议时间：2025年5月15-17日
◆ 会议地点：美国 奥兰多

◆ 会议简介：

2025年第34届美国临床内分泌学会(AACE)年会将于2025年5月15-17日在美国奥兰多良举行。AACE年会是临床内分泌学家和其他卫生保健专业人士参与的最重要的会议之一，会议为与会者提供了一个学习交流有关糖尿病、甲状腺功能异常、骨质疏松症、肥胖和其他代谢疾病患者所需的最新研究进展、措施和转化疗法的平台，预计有来自世界各地的3000余名专业人士参会。

美国临床内分泌学会(AACE)成立于1991年，是由专注于内分泌、糖尿病和新陈代谢的医师参与组成的大型专业组织，现在全球90多个国家和地区拥有超过7000名成员。AACE致力于提高其成员为患者提供高质量护理的能力。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

AACE 2025 – 34th Annual Meeting of the American Association of Clinical Endocrinology

Date: May 15–17, 2025
Venue: Hilton Orlando in Orlando, FL, United States

Each year, experts from the field of endocrinology convene to collaborate, learn and earn CME, CE and MOC through a combination of state-of-the-art-lectures, advanced learning experiences, engaging sessions, expert panel discussions, abstracts and more. This year, AACE is celebrating its 30 years of elevating endocrinology and improving global health!

Who Attends AACE's Annual Meeting?

Attendees are comprised of medical professionals from the field of clinical endocrinology at all stages in their career including clinical endocrinologists, general practitioners, nurse practitioners, nurses, allied health professionals, medical students, residents and fellows in training. With a wide array of educational options and continuing medical education offerings, participants can select to attend the sessions that are most relevant to their practice.

摘要征文：

AACE 2025 Annual Meeting Call for Abstracts

Call for Abstract Submissions Open： Tuesday, September 3, 2024
Call for Abstracts Submissions Closes： Monday, December 9, 2024. You will not be able to access your submission after 11:59 PM Eastern Standard Time on December 9, 2024. No exceptions.

点此提交摘要>>>Submit Abstract>>>

AACE will notify the submitter of the status of their abstract in mid-February 2025.

WHAT IS ELIGIBLE FOR SUBMISSION?

• Abstracts may be submitted by AACE Community Members or non-members. If you are not a member, you may join online at https://pro.aace.com/join-our-community. 
• Abstracts describing original research, clinical trials, or case studies/series related to the area of endocrinology may be submitted.
• Abstract submissions must be an original contribution and may not have previously been published or presented at any national/international meeting(s) in the same format at the time of abstract submission.
• By submitting your abstract, you agree to present the abstract if it is selected for presentation during the Annual Meeting.
• All accepted abstracts will be published as an online supplement to Endocrine Practice.
• If the abstract reports on the results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.
  Authorship on multiple abstracts is permitted.

WHAT IS NOT ELIGIBLE FOR SUBMISSION?

• The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
• Abstracts submitted for the late-breaking category cannot be submitted to another category.
• Abstracts previously published or presented at any national/international meeting are not eligible submissions.

ABSTRACT CATEGORIES

• Adrenal Disorders
• Diabetes/Prediabetes/Hypoglycemia
• Education/Quality Improvement
• Lipids/Cardiovascular Health
• Obesity/Nutrition
• Parathyroid/Bone Disorders
• Pediatric Endocrinology
• Pituitary Disorders/Neuroendocrinology
• Reproductive & Transgender Endocrinology
• Thyroid
• Others (genetic syndromes, new innovation, etc.)

ABSTRACT FORMAT
The abstract limit is 2,700 characters, including spaces. Count excludes the title, names of authors/co-authors, authors’ affiliations and disclosures.

TITLES

• Titles should be brief, clearly indicating the topic category (limited to 250 characters including spaces).
• Trial group names should not appear in the title.
• Enter the title in the “title” field only and do not enter the title in the body of the abstract.
• Author names and affiliations should not appear in the title.

Correct example: This is a Properly Formatted Abstract Title

AUTHORS

• Submitting authors will be the main contact for all correspondence during the submission process. NO EXCEPTIONS.
• Do not list authors or commercial relationships in the body of the abstract. Please consult with your co-authors on how they would like their names to appear prior to the submission of the abstract.
• There is a limit of 15 authors that may be included in the author block.

CONTENT

• Prior to submitting the abstract, please ensure that it is proofread by an individual who speaks fluent English and can make recommendations as needed.
• Preliminary or incomplete data are not allowed.
• Do not use new technical words, laboratory slang, words not defined in dictionaries, abbreviations, or terminology not consistent with internationally accepted guidelines. Define any abbreviations the first time they are used. Omit all names and geographical references in the body of the abstract. Organize content as follows:
  • Original Research/Clinical Trial
    • Objective: Background or Statement of Purpose
    • Methods: Methods, materials and analytical procedures used
    • Results: Summary of the results in sufficient detail to support conclusion
    • Discussion/Conclusion: Discuss the content and interpret the data
  • Case Study/Case Series
    • Background/Objective
    • Case report
    • Discussion
    • Conclusion

ABBREVIATIONS

• Use standard abbreviations. Place abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.

USE OF ACRONYMS

• AACE will only publish commonly used acronyms included in the unified list of acronyms approved by the principal journal editors in the field of endocrinology. Please refrain from using all trial group acronyms in abstract titles. Acronyms may remain in the body of the abstract and in the author list.

TABLES AND GRAPHICS
Tables, images, and/or graphs SHOULD NOT be submitted.

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。